8-K
filed May 13, 2026, 6:14 AM ET
ticker ZBIO
CIK 0001953926
earnings
confidence high
sentiment positive
materiality 0.55
Zenas BioPharma Q1 net loss $81M; obexelimab BLA on track
Zenas BioPharma, Inc.
- Net loss $81.0M in Q1 2026 vs $33.6M in Q1 2025; R&D expenses rose to $60.4M.
- Cash and investments $718.5M as of Mar 31; raised $419M year-to-date from offerings and debt facility.
- Obexelimab BLA for IgG4-RD expected this quarter; EMA filing H2 2026; INDIGO data at EULAR June 4.
- Phase 2 SunStone SLE trial enrollment completed; topline results expected Q4 2026.
- Director Tomas Kiselak did not stand for re-election; board size reduced by one.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Zenas BioPharma, Inc. reported financial results for the quarter ended March 31, 2026.
- Period
- the quarter ended March 31, 2026
- Result
- reported results
Exact text from the filing
On May 13, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tomas Kiselak resigned as director at Zenas BioPharma, Inc..
- Action
- resigned
Exact text from the filing
Tomas Kiselak did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Kiselak’s term ended with his resignation from the Board of Directors of the Company, and the size of the Board of Directors was reduced by one.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Zenas BioPharma, Inc. shareholders approved Election of two Class II directors to serve for three-year terms.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
Proposal One : The stockholders elected each of the two nominees listed below as Class II directors to serve on the Company’s Board of Directors for a term of three years expiring at the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes James Boylan 44,083,930 4,121,508 2,499 4,458,184 Patrick Enright 44,253,715 3,951,474 2,748 4,458,184
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Zenas BioPharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-12-31
Exact text from the filing
Proposal Two : The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 52,654,975 7,650 3,496
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.